Nuvilex (NASDAQ:PMCB) Trading Down 1.5% – Should You Sell?

by · The Markets Daily

Nuvilex Inc. (NASDAQ:PMCB – Get Free Report)’s share price traded down 1.5% during trading on Monday . The stock traded as low as $0.61 and last traded at $0.6233. Approximately 77,081 shares traded hands during trading, a decline of 3% from the average daily volume of 79,411 shares. The stock had previously closed at $0.6330.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Nuvilex in a report on Friday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

View Our Latest Analysis on Nuvilex

Nuvilex Stock Down 0.0%

The business has a 50-day simple moving average of $0.75 and a 200-day simple moving average of $0.75. The stock has a market cap of $6.55 million, a P/E ratio of -0.54 and a beta of 0.53.

Nuvilex Company Profile

(Get Free Report)

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.

See Also